ImaBiotech hires Florian Barré as Business Developer Europe
Lille, 17th January 2019
ImaBiotech is pleased to announce the hiring of Florian Barré as one of our new Business Developers in Europe. During his Ph.D. at Maastricht University (The Netherlands), Florian developed innovative mass spectrometry-based approaches and methods to detect pharmaceuticals in tissue using state-of-the-art mass spectrometry imaging (MSI).
Dr. Florian Barré has been trained as a Researcher since his Bachelor degree specializing in cell biology and physiology at the University of Lille (France). Florian then completed a Proteomics Masters at the same place and gained a lot of knowledge through his training focused on Mass Spectrometry, MALDI Imaging, and Medicine.
As a Marie Curie Early Stage Research Fellow at Maastricht MultiModal Molecular Imaging Institute (M4I) of Maastricht University, Division of imaging mass spectrometry, under the supervision of Prof. Ron Heeren and Dr. Berta Cillero Pastor, Florian contributed to the development a new MALDI source for high speed and spatial resolution in collaboration with a mass spectrometry company (Waters). Florian also studied the evaluation of advanced drug delivery carriers using MSI and worked on innovative sample preparation for drug detection including on-tissue chemistry and new instrumental development such as post-ionization MALDI (MALDI-2). In addition, he was an Imaging Consultant for a private company (HTX Imaging) and collaborated with drug discovery teams in pharmaceutical companies, bringing his expertise in MSI to study small molecule distributions in biological samples. Florian has also been heavily involved in the MSI community as an organizer of workshops and conferences (OurCon 2017).
As the Business Developer for South-Europe (France, Belgium, Italy, Spain, Switzerland,…), he is responsible for ImaBiotech’s European commercial activities. Florian is also in charge of building and maintaining successful relationships with new and existing customers in early phase (Preclinical – Drug Discovery, ADME, DMPK, and Toxicology) and late phase (Clinical) development, while conducting market analyses to identify target customers.
“Florian’s motivation and scientific knowledge will be a huge asset for the company” Jonathan Stauber, ImaBiotech’s founder.
Publications by Dr. F.Barré
|TITLE||AUTHORS||REVIEW||DATE OF PUBLICATION|
|Spatially resolved proteomics in osteoarthritis: State of the art and new perspectives|
MR Eveque-Mourroux, B Rocha, FPY Barré, RMA Heeren, B Cillero-Pastor
Journal of Proteomics
Advanced Mass Spectrometry Imaging: Pharmaceutical distributions and effects from Cartilage to Cancer
Florian PY Barré
Enhanced sensitivity using MALDI imaging coupled with laser postionization (MALDI-2) for pharmaceutical research
Florian PY Barré, Martin RL Paine, Bryn Flinders, Adam J Trevitt, Patrick D Kelly, Rima Ait-Belkacem, João P Garcia, Laura B Creemers, Jonathan Stauber, Rob J Vreeken, Berta Cillero-Pastor, Shane R Ellis, Ron MA Heeren
Development and evaluation of matrix application techniques for high throughput mass spectrometry imaging of tissues in the clinic
Lennart RS Huizing, Shane R Ellis, Bart WAMM Beulen, Florian PY Barré, Paul B Kwant, Rob J Vreeken, Ron MA Heeren
Clinical Mass Spectrometry
Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging
Berta Cillero-Pastor Florian P.Y. Barré, Britt S.R. Claes, Fréderic Dewez, Carine J. Peutz-Kootstra, Helga F. Munch-Petersen, Kirsten Grønbæk, Anders Lund, Ron M.A. Heeren, Christophe Roger Michel Côme
Faster raster matrix-assisted laser desorption/ionization mass spectrometry imaging of lipids at high lateral resolution
Tiffany Porta Siegel Florian Barré, Beatriz Rocha, Frédéric Dewez, Mark Towers, Paul Murray, Emmanuelle Claude, Berta Cillero-Pastor, Ron Heeren
Distribution, quantification and effects of triamcinolone acetonide in human osteoarthritic cartilage
FP Barré, M Paine, B Flinders, M Eveque-Mourroux, J Garcia, S Ellis, RM Heeren, L Creemers, B Cillero Pastor
Osteoarthritis and Cartilage
Mass Spectrometry Imaging in Nanomedicine: Unraveling the Potential of MSI for the Detection of Nanoparticles in Neuroscience
Florian PY Barre, Ron MA Heeren, Nina Ogrinc Potocnik
|Current Pharmaceutical Design|| |
Derivatization strategies for the detection of triamcinolone acetonide in cartilage by using matrix-assisted laser desorption/ionization mass spectrometry imaging
Florian PY Barré, Bryn Flinders, João P Garcia, Imke Jansen, Lennart RS Huizing, Tiffany Porta, Laura B Creemers, Ron MA Heeren, Berta Cillero-Pastor
ImaBiotech is a Contract Research Organization (CRO) with facilities in Boston (MA, USA) and Lille (Eurasanté Parc, France). The company offers innovative services and software to the pharmaceutical research sector, providing highly in vivoinformative drug efficacy and toxicity evaluations during preclinical and clinical stage developments at cellular level, making better and safer drugs.Services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) a technology developed and constantly improved by ImaBiotech. QMSI is a game changer for the pharmaceutical industry in all therapeutic areas. While other techniques provide global information, this molecular technique provides a deeper understanding of a drugs localization and its pharmacological effects at cellular level. This improves the interpretation of drug efficacy and toxicity, resulting in better drugs and decreasing time-to-market.
To learn more about ImaBiotech:
· Edma Fontaine – Communication and Marketing Manager
· email@example.com-+33 (0) 374095546